Synergy IB Investment

RnH-Bio is a biotechnology company that develops exosome-based products for various healthcare applications.

Eastech is a company that specializes in the research and development of drug substance candidates using 3D structural information analysis.

Cigro is a company that offers a data integration solution specifically designed for e-commerce operators. It operates a performance management platform that automatically collects and links data from various sales and advertising channels. This integration allows businesses to access comprehensive reports and insights through a user-friendly dashboard. By providing daily performance notifications, Cigro enables its clients to make informed decisions based on real-time data, ultimately enhancing their e-commerce operations.

SOS Lab is a specialized company that develops and manufactures LiDAR technology, which utilizes lasers to measure distances and shapes of surrounding environments. The company focuses on creating innovative solutions for self-driving cars, highlighted by its hybrid LiDAR system, the SL-1. This long-range system combines traditional motor scanning with a solid-state MEMS mirror, offering a more affordable option compared to existing products in the market. In addition to the SL-1, SOS Lab provides two other LiDAR products, the GL-3 for factory automation and robotics, and the TL-3 for security and automatic doors. The company aims to enhance its offerings by integrating hardware-based sensors with AI-driven object recognition and tracking technologies, using 3D point cloud data. SOS Lab collaborates with automotive electronics partners and global semiconductor firms to advance its next-generation Solid-State LiDAR. With research and development centers in Seoul and Gwangju, alongside business operations in Silicon Valley, SOS Lab seeks to expand its global presence and contribute to the self-driving and advanced driver-assistance systems (ADAS) markets.

Lysentech is a biotechnology company focused on developing novel treatments for antibiotic-resistant bacteria. The company's primary expertise lies in utilizing bacteriophages and phage-derived endolysins to create effective antibiotics. Additionally, Lysentech is advancing the development of oncolytic bacteriophages that specifically target cancer cells, providing a potential new approach for delivering anticancer therapies. By harnessing the unique properties of bacteriophages, Lysentech aims to address critical healthcare challenges posed by antibiotic resistance and improve cancer treatment outcomes.

Study Senior is a company that specializes in educational assistance through an online-to-offline platform. It has developed an application-based school discovery platform aimed at facilitating the school selection process for parents and students. The platform provides a comprehensive suite of resources, including promotional videos and images of schools, geographical information, automatic call connection features, and user reviews. By offering these tools, Study Senior helps users make informed decisions when choosing educational institutions.

Larchive monitors import and export supply chains for risk management through its intelligence services.

Rznomics is a biotechnology company founded by Professor Lee Sung-wook's lab, specializing in the development of ribonucleic acid-based gene therapies. The company focuses on creating innovative biopharmaceuticals aimed at addressing significant medical challenges, particularly in the treatment of liver cancer, various cancers, degenerative neurological diseases, and hereditary disorders. Rznomics has been recognized for its technological advancements and was selected by the TIPS program, highlighting its commitment to addressing medical needs that remain unmet in current healthcare. Through its research and development efforts, Rznomics aims to enable medical practitioners to effectively treat complex conditions such as cancer and Alzheimer's disease.

CK Regeon is a biotechnology company focused on improving human health through innovative drug development. The company specializes in creating small molecules and peptides designed to treat various metabolic disorders. Its research targets specific diseases such as obesity, diabetes, and non-alcoholic steatohepatitis, while also addressing conditions related to hair growth and wound healing. By developing targeted compounds, CK Regeon aims to provide effective therapeutic solutions that enhance the quality of life for patients suffering from these health issues.

Huinno, Inc. is a healthcare technology company established in 2014 and headquartered in Boston, Massachusetts, with additional offices in New York and Seoul. The company specializes in developing advanced healthcare devices designed to monitor vital health data, including blood pressure, heart rate, electrocardiograms (ECG), and blood oxygen saturation levels. Utilizing proprietary wearable devices along with AI-based analytics, Huinno aims to transform the management of chronic cardiac diseases by providing continuous, real-time health monitoring with clinical-grade accuracy. Their platform includes an application and a cloud-based ecosystem that facilitates longitudinal trend analysis of patients' health metrics, medication compliance, and lifestyle habits. By offering healthcare providers a robust remote patient monitoring solution, Huinno enhances chronic disease prevention and reduces hospital readmission rates, ultimately supporting clinicians in making informed medical decisions.

SnackFever Inc. is a subscription-based service that specializes in delivering a variety of snacks, candies, drinks, ramen products, and other treats from Korea to customers in the United States. Founded in 2015 and headquartered in Los Angeles, California, the company caters to fans of Korean culture by providing monthly shipments of popular Korean food items. SnackFever aims to create an engaging experience for its subscribers by offering a curated selection of products that reflect the vibrant culinary landscape of Korea.

Rznomics is a biotechnology company founded by Professor Lee Sung-wook's lab, specializing in the development of ribonucleic acid-based gene therapies. The company focuses on creating innovative biopharmaceuticals aimed at addressing significant medical challenges, particularly in the treatment of liver cancer, various cancers, degenerative neurological diseases, and hereditary disorders. Rznomics has been recognized for its technological advancements and was selected by the TIPS program, highlighting its commitment to addressing medical needs that remain unmet in current healthcare. Through its research and development efforts, Rznomics aims to enable medical practitioners to effectively treat complex conditions such as cancer and Alzheimer's disease.

Enfusion is a developer of mobile and PC games

Huinno, Inc. is a healthcare technology company established in 2014 and headquartered in Boston, Massachusetts, with additional offices in New York and Seoul. The company specializes in developing advanced healthcare devices designed to monitor vital health data, including blood pressure, heart rate, electrocardiograms (ECG), and blood oxygen saturation levels. Utilizing proprietary wearable devices along with AI-based analytics, Huinno aims to transform the management of chronic cardiac diseases by providing continuous, real-time health monitoring with clinical-grade accuracy. Their platform includes an application and a cloud-based ecosystem that facilitates longitudinal trend analysis of patients' health metrics, medication compliance, and lifestyle habits. By offering healthcare providers a robust remote patient monitoring solution, Huinno enhances chronic disease prevention and reduces hospital readmission rates, ultimately supporting clinicians in making informed medical decisions.

AptaBio Therapeutics Inc. is a pharmaceutical biotechnology company based in Yongin-Si, South Korea, focused on discovering and developing innovative treatments, particularly selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers a range of transfection reagents, including Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX, designed to facilitate the introduction of DNA or RNA into eukaryotic cells. AptaBio's product pipeline includes several candidates, such as PX-115 for diabetic nephropathy, APX-1004 for diabetic retinopathy, and APX-311 intended for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics aims to address significant medical needs through its innovative drug development efforts.

Neuroventi is a company focused on developing customized solutions and therapies for brain development disorders, specifically targeting conditions such as autism spectrum disorder and attention deficit hyperactivity disorder. The firm employs innovative approaches to address various molecular processes involved in these disorders, enhancing the efficacy of treatment options for medical professionals. In addition to its therapeutic developments, Neuroventi also offers drug discovery services for natural products, further contributing to the advancement of treatments for neurological conditions. The company's mission centers on providing effective interventions that support brain function and overall cognitive health.